Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 196 AL 210

A review on cholinesterase inhibitors for Alzheimer's disease

Anand P, Singh B.

Arch Pharm Res. 2013 Apr;36(4):375-99. doi: 10.1007/s12272-013-0036-3. Epub 2013 Feb 24.

[Cholesterol inhibitor and memantine in symptomatic dementia therapy]

Rodda J, Carter J.

Praxis (Bern 1994). 2013 Feb 27;102(5):293-300; discussion 298-9. doi: 10.1024/1661-8157/a001209.

PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease

O' Neill C.

Exp Gerontol. 2013 Jul;48(7):647-53. doi: 10.1016/j.exger.2013.02.025. Epub 2013 Mar 5.

Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia

Silva AC, González-Mira E, Lobo JM, Amaral MH.

Curr Pharm Des. 2013;19(41):7185-95. doi: 10.2174/138161281941131219123329.

Aspects of communication in Alzheimer's disease: clinical features and treatment options

Woodward M.

Int Psychogeriatr. 2013 Jun;25(6):877-85. doi: 10.1017/S1041610213000318. Epub 2013 Mar 25.

Rivastigmine patch and massage for Alzheimer's disease patients

Satoh S, Kajiwara M, Kiyokawa E, Toukairin Y, Fujii M, Sasaki H.

Geriatr Gerontol Int. 2013 Apr;13(2):515-6. doi: 10.1111/ggi.12010.

Acute dystonic reaction with rivastigmine

Dhikav V, Anand KS.

Int Psychogeriatr. 2013 Aug;25(8):1385-6. doi: 10.1017/S104161021300029X. Epub 2013 Apr 8.

Vascular contribution to Alzheimer disease: predictors of rapid progression

Diomedi M, Misaggi G.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):532-7. doi: 10.2174/1871527311312040015.

Diagnosis and management of Alzheimer's disease: past, present and future ethical issues

Gauthier S, Leuzy A, Racine E, Rosa-Neto P.

Prog Neurobiol. 2013 Nov;110:102-13. doi: 10.1016/j.pneurobio.2013.01.003. Epub 2013 Apr 8.

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings

Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, Argimon JM, Bruno G, Novick D, Vellas B, Haro JM.

J Alzheimers Dis. 2013;36(2):385-99. doi: 10.3233/JAD-122392.

Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial

Reckess GZ, Brandt J, Luis CA, Zandi P, Martin B, Breitner JC; ADAPT Research Group.

J Alzheimers Dis. 2013;36(3):433-43. doi: 10.3233/JAD-130113.

Exploring sleep-related outcomes in patients with mild to moderate Alzheimer's disease initiating acetylcholinesterase inhibitor therapy: the Morpheus survey

Petiau C, Onen H, Delgado A, Touchon J.

Int J Geriatr Psychiatry. 2013 Jun;28(6):657-9. doi: 10.1002/gps.3896.

Missing data analysis in drug-naïve Alzheimer's disease with behavioral and psychological symptoms

Kwak YT, Yang Y, Park SG.

Yonsei Med J. 2013 Jul;54(4):825-31. doi: 10.3349/ymj.2013.54.4.825.

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

Freiherr J, Hallschmid M, Frey WH 2nd, Brünner YF, Chapman CD, Hölscher C, Craft S, De Felice FG, Benedict C.

CNS Drugs. 2013 Jul;27(7):505-14. doi: 10.1007/s40263-013-0076-8.

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, Jia XD, Pejović V, Miller ML, Perhach JL, Graham SM.

CNS Drugs. 2013 Jun;27(6):469-78. doi: 10.1007/s40263-013-0077-7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias